


## 4-Hydroxy Atorvastatin calcium salt

## Chemical Properties

CAS No. :	265989-44-4
Formula:	C <sub>66</sub> H <sub>68</sub> CaF <sub>2</sub> N <sub>4</sub> O <sub>12</sub>
Molecular Weight:	1187.34
Storage:	Store at low temperature Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	4-Hydroxy Atorvastatin calcium salt is metabolised by cytochrome P450 CYP3A4 and has antimicrobial and anti-microbial activity. Atorvastatin is a lipid-lowering HMG-CoA reductase inhibitor.
Targets(IC50)	HMG-CoA Reductase, Drug Metabolite

## Solubility Information

Solubility	DMF: 16 mg/mL (13.48 mM), Sonication is recommended. DMSO: 80 mg/mL (67.38 mM), Sonication is recommended. PBS (pH 7.2) (1:9): < 0.1: < 1 mg/mL (insoluble) DMF:PBS (pH 7.2) (1:9): 0.1 mg/mL (0.08 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (2.78 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	0.8422 mL	4.2111 mL	8.4222 mL
5 mM	0.1684 mL	0.8422 mL	1.6844 mL
10 mM	0.0842 mL	0.4211 mL	0.8422 mL
50 mM	0.0168 mL	0.0842 mL	0.1684 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Jiang Z, et al. Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease. *Front Pharmacol.* 2023 Feb 27;14:1102810.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481